Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, phase II/III, open-label, randomized, parallel and standard
chemoradiation-controlled study where eligible subjects will be randomized at 1:1 ratio to
receive control treatment or study treatment. The primary objective of this trial is to
evaluate the effect of add-on JP001 to standard chemoradiation in increasing overall survival
(OS) on newly diagnosed glioblastoma (GBM) patients.